head and neck cancer
TheraVectys Launches Phase I/IIa Trial of HPV-Targeted Vaccine in Cervical, Oropharyngeal Cancers
The trial will include patients with newly diagnosed, treatment-naïve cancers as well as those with recurrent or metastatic disease.
A study presented at the ESMO Congress shed light on an ADC directed against an immune checkpoint in PD-L1-expressing solid cancers.
Biosyngen to Begin Phase II Study of CAR T-Cell Therapy in EBV-Positive Nasopharyngeal Carcinoma
A Phase I trial showed that Biosyngen's EBV-specific CAR T-cell therapy BRG01 was safe and well tolerated with early signs of efficacy.
GC Cell, Lukas Biomedical Team up to Advance Autologous Cell Therapies
The Korean and Taiwanese biotechs will share research and collaborate on clinical trials to bring their cell therapies to more patients in Southeast Asia and globally.
KSQ Therapeutics Treats First Patient in Phase I/II Trial of Engineered TIL Therapy
The firm believes that its eTIL therapy, which it is evaluating in melanoma, NSCLC, and head and neck cancer, has advantages over unmodified TIL therapy.